Radial Extracorporeal Shock Wave Treatment for Chronic Plantar Fasciopathy
Launched by PROF. DR MAHMOUD IBRAHIM IBRAHIM · Feb 7, 2016
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Plantar fasciitis, the most common cause of heel pain, accounts for approximately 11-15% of foot symptoms presenting to physicians. In the United States, more than two million individuals are treated for PF on an annual basis. The term Plantar Fasciitis implies an inflammatory condition by the suffix 'itis'. However, various lines of evidence indicate that this disorder is better classified as 'fasciosis' or 'fasciopathy'. Details about etiology, pathogenesis, risk factors, diagnosis and general treatment strategies for plantar fasciitis have been provided in a series of comprehensive revie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults over the age of 18 years
- • Diagnosis of painful heel syndrome by clinical examination, with the following positive clinical signs: (i) pain in the morning or after sitting a long time; (ii) local pain where the fascia attaches to the heel; and (iii) increasing pain with extended walking or standing for more than 15 minutes
- • History of six months of unsuccessful conservative treatment
- • Therapy free period of at least four weeks before referral
- • Signed informed consent
- Exclusion Criteria:
- • Bilateral plantar fasciitis
- • Dysfunction of foot or ankle (for example, instability)
- • Arthrosis or arthritis of the foot
- • Infections or tumors of the lower extremity
- • Neurological abnormalities, nerve entrapment (for example, tarsal tunnel syndrome)
- • Vascular abnormality (for example, severe varicosities, chronic ischemia)
- • Operative treatments of the heel spur
- • Hemorrhagic disorders and anticoagulant therapy
- • Pregnancy
- • Diabetes
About Prof. Dr Mahmoud Ibrahim Ibrahim
Prof. Dr. Mahmoud Ibrahim Ibrahim is a distinguished clinical trial sponsor with extensive expertise in medical research and patient care. He is renowned for his contributions to the field, focusing on innovative therapeutic approaches and the advancement of clinical methodologies. With a commitment to ethical research practices and patient safety, Prof. Ibrahim leads clinical trials aimed at evaluating the efficacy and safety of novel treatments. His leadership and collaborative efforts foster a rigorous research environment that prioritizes scientific integrity and the well-being of participants, ultimately contributing to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Mahmoud I Ibrahim, PhD, PT
Principal Investigator
Rocky Mountain University of Health Professions, Provo, UT 84601, USA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials